Ischemic Stroke Lab is pleased to announce that the Ischemia Care company laboratory has reached an important milestone in the path to clinical availability of the ISCDx test with the recent CLIA active status designation for the Franklin, Ohio laboratory facility. This status is granted after application to the Centers for Medicare and Medicaid Services (CMS).
Company CEO Jeff June commented, “This achievement is the result of an incredible Ischemia Care laboratory staff, led by Judy Morgan, Director of Laboratory Operations, that worked diligently to bring a lab into commercial readiness from an empty facility.It is also an important step for the thousands of stroke patients that contributed blood samples to BASE clinical trial used in the CLIA process, we look forward to applying what we have accomplished to millions more stroke patients in the future”.
Processing the ISCDx test involves isolating and analyzing RNA levels from a small sample of blood collected in the hospital, in order to identify the pattern of gene activity unique to different causes of stroke.
Comments